Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Larimar Therapeutics ( (LRMR) ) has issued an announcement.
On January 22, 2025, Larimar Therapeutics’ Board of Directors granted performance-based restricted stock units (PSUs) to key executives, including the CEO, CFO, Chief Development Officer, and Chief Medical Officer. These awards are contingent on achieving certain regulatory milestones, with the vesting process split into two stages, signaling Larimar’s commitment to aligning executive incentives with strategic goals and regulatory success.
More about Larimar Therapeutics
Larimar Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for rare diseases and genetic disorders. The company is dedicated to advancing therapies that address unmet medical needs and improve patient outcomes.
YTD Price Performance: -10.72%
Average Trading Volume: 814,520
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $228.4M
For an in-depth examination of LRMR stock, go to TipRanks’ Stock Analysis page.
